PeptidePedia The community reference

Contributions of NPOV_Nadia

User contributions·152 logged edits·page 1 of 2

Contributions by NPOV_Nadia, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 24,117 edits includes activity predating the current log.

  1. 18:00, 26 Jul 2026 (diff | hist) Thermo Fisher Scientific (China) 18,573 ±0 add the reception tally with its period and count stated
  2. 12:40, 20 Jul 2026 (diff | hist) Talk:Asymchem Laboratories 748 +346 /* Four reports against one lot: what does that actually establish? */ reply
  3. 00:28, 15 Jul 2026 (diff | hist) Deamidation 5,263 ±0 m ce
  4. 15:39, 14 Jul 2026 (diff | hist) International nonproprietary name 4,356 ±0 alphabetise the see-also list
  5. 15:15, 28 Jun 2026 (diff | hist) Talk:Batch number 885 +153 /* Documentary observation versus allegation */ reply
  6. 14:35, 27 Jun 2026 (diff | hist) Talk:Sterility testing 885 +87 /* Treat as non-sterile */ reply
  7. 10:05, 27 Jun 2026 (diff | hist) Hubei Jianxiang Bioscience 14,855 ±0 add the minimum order quantity for custom synthesis
  8. 10:20, 24 Jun 2026 (diff | hist) Talk:List of GLP-1 receptor agonists 537 +153 /* Inclusion is not endorsement */ new section
  9. 02:19, 13 Jun 2026 (diff | hist) Missed dose 5,277 ±0 state the syringe graduation the unit figure assumes
  10. 11:30, 5 Jun 2026 (diff | hist) Talk:Peptide aggregation 674 +175 /* Handling practices */ new section
  11. 12:44, 2 Jun 2026 (diff | hist) Talk:Insulin secretion 885 +132 /* Which secretion index should the article recommend? */ reply
  12. 13:40, 19 May 2026 (diff | hist) Talk:Test report forgery 885 +124 /* Naming suppliers */ reply
  13. 01:01, 17 May 2026 (diff | hist) Arcuate nucleus 5,251 ±0 give the fasting and postprandial concentrations with the assay named
  14. 14:35, 16 May 2026 (diff | hist) Talk:Third-party testing 885 +207 /* Should the service comparison table rank them? */ reply
  15. 22:11, 13 May 2026 (diff | hist) Beta cell function 6,096 ±0 add the enteroendocrine cell type responsible for secretion
  16. 13:55, 6 May 2026 (diff | hist) Talk:Personal importation policy 748 +67 /* Community reports as evidence */ reply
  17. 09:30, 19 Apr 2026 (diff | hist) Talk:Dose escalation schedule 537 +170 /* Schedule table is descriptive */ new section
  18. 13:15, 15 Apr 2026 (diff | hist) Talk:Global access disparity 611 +145 /* Framing of the access argument */ reply
  19. 10:20, 8 Apr 2026 (diff | hist) Talk:Customs seizure 537 +149 /* No avoidance methods */ new section
  20. 12:30, 5 Apr 2026 (diff | hist) Talk:PeptideMeter 748 +161 /* Should we import external tallies? */ reply
  21. 15:02, 2 Apr 2026 (diff | hist) Talk:Cold chain 1,370 +367 /* RfC: should this article cover consumer shipping practice? */ reply
  22. 13:25, 31 Mar 2026 (diff | hist) Talk:Cost per milligram 611 +74 /* The comparison cannot be made */ reply
  23. 09:44, 31 Mar 2026 (diff | hist) Talk:Multi-dose vial 1,233 +253 /* Weight of the outbreak section */ reply
  24. 09:15, 28 Mar 2026 (diff | hist) Talk:Reconstitution of lyophilised peptides 959 +81 /* Register: description or instruction? */ reply
  25. 10:40, 27 Mar 2026 (diff | hist) Talk:Reconstitution of lyophilised peptides 537 +210 /* Register: description or instruction? */ new section
  26. 08:54, 17 Mar 2026 (diff | hist) SUSTAIN trial programme 5,153 ±0 m name the funder in the sentence, per PP:MOS
  27. 11:40, 15 Mar 2026 (diff | hist) Talk:Enteroendocrine L cell 537 +257 /* Microbiome mention feels speculative */ new section
  28. 13:25, 11 Mar 2026 (diff | hist) Talk:Baseline laboratory panel 611 +87 /* Table is not a recommendation */ reply
  29. 10:44, 8 Mar 2026 (diff | hist) Talk:Sigma-Aldrich (Shanghai) Trading 1,170 +117 /* Trading company or synthesis house, and whether the article should say */ reply
  30. 11:15, 18 Feb 2026 (diff | hist) Talk:Glucose-dependent insulinotropic polypeptide 885 +412 /* Requested move: → GIP */ reply
  31. 11:45, 15 Feb 2026 (diff | hist) Talk:Incretin effect 1,096 +72 /* Type 1 diabetes section may be original research */ reply
  32. 08:26, 15 Feb 2026 (diff | hist) Talk:PolyPeptide Group (Hangzhou) 1,170 +144 /* A printed trace and a filled vial are not the same object */ reply
  33. 15:22, 14 Feb 2026 (diff | hist) Talk:Incretin effect 674 +330 /* Type 1 diabetes section may be original research */ new section
  34. 09:05, 13 Feb 2026 (diff | hist) Talk:Janoshik Analytical 822 +88 /* Conflict of interest disclosure */ reply
  35. 09:18, 12 Feb 2026 (diff | hist) Talk:Reconstitution calculator 1,233 +110 /* Requested move: → Peptide reconstitution calculator */ reply
  36. 13:22, 11 Feb 2026 (diff | hist) Talk:AmbioPharm 748 +248 /* Should the stock position sit in §Operations or §Reception? */ reply
  37. 13:05, 11 Feb 2026 (diff | hist) Talk:SinoPep 748 +213 /* Whether the counter-ion figure belongs in the lead */ reply
  38. 10:48, 6 Feb 2026 (diff | hist) Talk:Beyond-use date 1,244 +241 /* RfC: are beyond-use date and expiration date being conflated across the wiki? */ reply
  39. 09:50, 31 Jan 2026 (diff | hist) Talk:Insulin syringe 400 +203 /* Table is arithmetic, not guidance */ new section
  40. 13:25, 30 Jan 2026 (diff | hist) Talk:Weight regain after discontinuation 611 +133 /* Lifelong treatment claim */ reply
  41. 13:48, 22 Jan 2026 (diff | hist) Talk:Glucagon-like peptide-1 1,022 +346 /* Requested move: → GLP-1 */ reply
  42. 13:22, 14 Jan 2026 (diff | hist) Talk:GenScript Peptides 748 +220 /* Does "synthesis house" belong in the first sentence? */ reply
  43. 13:15, 13 Jan 2026 (diff | hist) Talk:Peptide harm reduction 611 +104 /* Where the line sits */ reply
  44. 21:18, 14 Dec 2025 (diff | hist) Reconstitution calculator 8,662 ±0 add the reset control description
  45. 09:37, 3 Dec 2025 (diff | hist) Talk:Xi'an Mokemei Biotechnology 822 +297 /* Should the lot-identifier check be described on every supplier article? */ reply
  46. 17:11, 2 Dec 2025 (diff | hist) International nonproprietary name 4,356 ±0 add a hatnote pointing at the analogue with the similar name
  47. 16:45, 22 Nov 2025 (diff | hist) Growth hormone secretagogue 4,613 ±0 consistent en dashes in ranges
  48. 13:30, 19 Nov 2025 (diff | hist) Chain of custody 5,157 ±0 state what the certificate actually carries, field by field
  49. 09:22, 12 Nov 2025 (diff | hist) Talk:Vial 1,096 +146 /* The unmarked-vial paragraph is close to describing evasion */ reply
  50. 12:14, 11 Nov 2025 (diff | hist) Talk:Vial 674 +317 /* The unmarked-vial paragraph is close to describing evasion */ new section
  51. 17:40, 13 Oct 2025 (diff | hist) Certificate of analysis 10,014 +200 state that the report identifies the sample, not the shipment
  52. 09:12, 9 Oct 2025 (diff | hist) Talk:Chinese Peptide Company 959 +232 /* The water-figure observation — are we praising a supplier? */ reply
  53. 10:18, 3 Oct 2025 (diff | hist) Talk:AmbioPharm 822 +378 /* Notability, and what a long registry record does not establish */ reply
  54. 19:58, 25 Sep 2025 (diff | hist) Intention-to-treat analysis 4,963 ±0 ce
  55. 17:03, 12 Sep 2025 (diff | hist) Flourishglobal Peptide Biotech 10,704 +1,131 space between number and unit per PP:MOS
  56. 15:18, 5 Sep 2025 (diff | hist) Talk:GenScript Peptides 1,033 +449 /* Notability, and what a long registry record does not establish */ reply
  57. 09:06, 3 Sep 2025 (diff | hist) Talk:Shenzhen Hybio Pharmaceutical 959 +284 /* Is "contract manufacturer" a description or a claim? */ reply
  58. 10:54, 22 Aug 2025 (diff | hist) Peptide content 8,131 ±0 expand §What occupies the rest of the mass
  59. 02:06, 28 Jul 2025 (diff | hist) Karl Fischer titration 8,741 +435 m space between number and unit per PP:MOS
  60. 06:37, 26 Jul 2025 (diff | hist) Peptide stability table 5,406 +284 expand §How to read the columns
  61. 16:58, 16 Jul 2025 (diff | hist) Trial data comparison 5,621 ±0 m clarify which figures are measured and which are derived
  62. 13:27, 30 Jun 2025 (diff | hist) Talk:Qingdao Saber Technology Pharmaceutical 611 +154 /* Two organisations, one city, similar names */ reply
  63. 08:09, 24 Jun 2025 (diff | hist) Vial 21,712 +1,439 state that a phase-change pack and a gel pack behave differently
  64. 22:05, 16 Jun 2025 (diff | hist) Peptide stability table 5,122 +231 add the medical-disclaimer cross-link to the tool pages
  65. 11:20, 13 Jun 2025 (diff | hist) Talk:SinoPep 1,033 +172 /* Notability, and whether a documentary distinction is a notable one */ reply
  66. 04:32, 27 May 2025 (diff | hist) Trifluoroacetate counterion 3,899 ±0 add the figure for the chromatogram and caption its axes
  67. 09:26, 3 May 2025 (diff | hist) Talk:Hubei Jianxiang Bioscience 822 +182 /* Dispatch address versus registered address */ reply
  68. 08:52, 29 Apr 2025 (diff | hist) Talk:Qingdao Sigma Chemical 959 +300 /* Reporting a tally count without implying a ranking */ reply
  69. 12:44, 27 Apr 2025 (diff | hist) Vial filling and stoppering 4,012 ±0 state the residual-moisture target with the method it is measured by
  70. 14:16, 23 Apr 2025 (diff | hist) Repackaging 3,958 ±0 m add the note that lyophilised material tolerates excursions better than solution
  71. 09:03, 15 Apr 2025 (diff | hist) Talk:Blind sampling 959 +122 /* Selection on the outcome is a third failure, not a footnote */ reply
  72. 11:27, 9 Apr 2025 (diff | hist) Talk:Wuhan Wansheng Biotechnology 1,033 +261 /* RfC: what does a large report set actually support? */ reply
  73. 05:13, 6 Apr 2025 (diff | hist) Medutest 3,795 ±0 m split §What a report shows from §What it does not
  74. 21:10, 22 Feb 2025 (diff | hist) Peptide supply chain 5,316 +135 alphabetise the see-also list
  75. 08:08, 9 Feb 2025 (diff | hist) Insulin syringe unit conversion 3,540 +335 add category for interactive reference tools
  76. 11:08, 4 Feb 2025 (diff | hist) Talk:Shanghai Wibson Biotechnology 1,033 +226 /* Notability: what a five-year registry history establishes */ reply
  77. 22:49, 18 Jan 2025 (diff | hist) Fmoc chemistry 3,718 ±0 rm the blanket claim that excursions are harmless
  78. 13:07, 16 Jan 2025 (diff | hist) Talk:Bachem Holding (Suzhou) 611 +299 /* The name coincidence: how much should the article say? */ reply
  79. 15:19, 28 Dec 2024 (diff | hist) Medutest 3,491 +111 clarify that agreement between certificate and report is a weak finding
  80. 18:04, 20 Dec 2024 (diff | hist) Batch number 3,377 +364 add the note on how to request a batch record rather than a certificate
  81. 12:07, 20 Dec 2024 (diff | hist) Custom peptide synthesis 2,690 ±0 state that overlay gas is used and name it
  82. 16:14, 7 Dec 2024 (diff | hist) VendorInvestigate 3,440 +559 m convert the service comparison to a table
  83. 09:36, 6 Dec 2024 (diff | hist) Talk:GL Biochem (Shanghai) 822 +312 /* Supporter disclosure and article neutrality */ reply
  84. 03:22, 29 Oct 2024 (diff | hist) Insulin syringe unit conversion 1,495 +33 correct the column header — that column is volume
  85. 18:29, 27 Oct 2024 (diff | hist) Purity claim inflation 2,238 ±0 m state what the certificate actually carries, field by field
  86. 14:08, 14 Oct 2024 (diff | hist) Talk:Hunan Aslsen Technology 611 +237 /* "Verified by" is not a test result */ reply
  87. 14:23, 3 Oct 2024 (diff | hist) Triple agonist 2,043 ±0 add the receptor targets to the lead sentence
  88. 11:18, 14 Sep 2024 (diff | hist) Chinese Peptide Company 4,118 +696 m expand §Product range
  89. 09:41, 4 Sep 2024 (diff | hist) Albumin binding half-life extension 2,425 +2,425 N start article on the hormone
  90. 09:52, 28 Aug 2024 (diff | hist) Talk:Guangzhou JEEP Biotechnology 822 +234 /* Concentrated catalogue makes the report set more interpretable */ reply
  91. 09:14, 13 Aug 2024 (diff | hist) Talk:WuXi TIDES 822 +79 /* Notability, and the name problem */ reply
  92. 10:22, 12 Aug 2024 (diff | hist) Talk:WuXi TIDES 400 +516 /* Notability, and the name problem */ new section
  93. 09:00, 2 Aug 2024 (diff | hist) Chinese Peptide Company 1,746 +1,746 N create organisation article per PP:VN
  94. 15:58, 25 Jul 2024 (diff | hist) Lot traceability 1,389 ±0 correct the description of how lot identifiers are assigned
  95. 01:32, 24 Jul 2024 (diff | hist) GLP-1 receptor agonist 2,788 ±0 state the substitution in one-letter code as well, per PP:MOS
  96. 08:57, 6 Jul 2024 (diff | hist) Talk:AmbioPharm 1,307 +122 /* Standing note: what this article may not contain */ reply
  97. 08:57, 6 Jul 2024 (diff | hist) Talk:Asymchem Laboratories 1,307 +122 /* Standing note: what this article may not contain */ reply
  98. 08:57, 6 Jul 2024 (diff | hist) Talk:Bachem Holding (Suzhou) 1,307 +122 /* Standing note: what this article may not contain */ reply
  99. 08:57, 6 Jul 2024 (diff | hist) Talk:ChinaPeptides 1,307 +122 /* Standing note: what this article may not contain */ reply
  100. 08:57, 6 Jul 2024 (diff | hist) Talk:Chinese Peptide Company 1,307 +122 /* Standing note: what this article may not contain */ reply